Partnership to Accelerate Product Development and Path to Market Within Manufacturing Supply Chains Including Leather

STONY BROOK, N.Y. – April 12, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a non-binding Memorandum of Understanding (“MOU”) with Netherlands-based Stahl, the world leader in process chemicals for leather products, performance coatings and other substrates. The MOU is expected to be followed by a definitive agreement.

Under the terms of the MOU, the parties will continue the evaluation of molecular tagging of process chemicals and coatings utilizing Stahl’s product offerings as a point of entry into supply chains for the Company’s molecular tags. Stahl will provide technical expertise to the company relating to the process chemicals used in leather manufacturing.

Dr. James Hayward, President and CEO of Applied DNA, said, “Stahl’s global sales and support footprint, coupled with broad access to its customer base that spans global brands and their supply chains, makes it an ideal partner through which to expand, implement and support our CertainT® authentication and traceability platform. We believe this partnership should accelerate our entry into the leather market. We look forward to a long and productive relationship with Stahl.”

Mike Costello, Director of Sustainability at Stahl, said “We see a bright future for molecular tagging. Leather is just one of many industries which could benefit by having the capability to improve traceability. As a process chemical manufacturer, we are a logical point of entry into a whole range of supply chains for Applied DNA’s molecular tags.”

About Stahl
Stahl is the world leader in leather chemicals and high-performance coatings. Our products provide functionality, durability and comfort to many different materials used in everyday life. Through our continuous focus on innovation and improving the environmental footprint, Stahl adds value to differentiated high-end industries with a unique service model for premium solutions. As part of its corporate responsibility, Stahl is actively driving change in the industry by initiating activities that promote transparency and to provide environmental solutions for the supply chain, involving close collaboration with its partners.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anticounterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates. Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com

Short fragments of linear DNA are used for molecular tagging in a variety of industries, from textiles to pharmaceuticals, to provide product authentication and ingredient traceability. Applied DNA Sciences is now translating its expertise in the molecular tagging industry to the biopharma industry. Its subsidiary, LineaRx, is manufacturing large, gene-sized fragments of linear DNA for companies researching or developing gene-based therapies or diagnostics, as well as for its own gene therapy program. This parallel path to growth addresses both the development and distribution sides of the biopharma industry, which bodes well for overall organizational success.

The parent company’s short fragments and the subsidiary’s long fragments both involve the large-scale production of specific DNA sequences using the polymerase chain reaction (PCR). Alongside this commonality, there is this significant difference: The short fragments are nonfunctional, whereas the long fragments are functional (and suitable for therapeutic applications).

Novel DNA Manufacturing Platform Seeks to Pioneer New Generation of Faster, More Affordable Cell-based Therapeutics for Patients

STONY BROOK N.Y., April 8, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that LineaRx, (the “Company”), its subsidiary focused on next-generation biotherapeutics, has achieved anti-CD-19 CAR (Chimeric Antigen Receptor) expression in human T Cells via its proprietary, non-viral, plasmid-free (NVPF) manufacturing platform. To the Company’s knowledge, this seminal event represents the first time that a human T cell has been shown to express an anti-CD19 CAR from a gene construct utilizing linear DNA produced via a scalable PCR (Polymerase Chain Reaction) manufacturing process. The Company views this development as an important option for all gene therapies that currently use virus-delivery platforms, but especially for immune-oncology therapies that use virus delivery of synthetic genes to redirect a patient’s T cells, known as CAR therapy.

LineaRx’s unique PCR-based manufacturing technology created the linear DNA amplicon encoding the anti-CD19 engager, and that construct was then electroporated into human T cells ex vivo.  Subsequent testing has yielded anti-CD19 expression from these engineered cells.  While these preliminary data are encouraging, overall levels of expression were initially low and LineaRx continues working on generating higher transfection levels using the patent-pending High Expression Amplicon (HEA™) and methods of transfection other than electroporation and will report further progress on this significant achievement as it emerges.

Dr. James A. Hayward, president and CEO of Applied DNA, stated: “Our goals are three-fold: 1) To establish the value of PCR-produced linear DNA as a platform for the rapid design and production of therapeutic nucleic acid constructs, including at the point of care; 2) To prove the improved safety and therapeutic value of NVPF production streams, which are distinct from industry-wide viral-based production; and, 3) To bring our NVPF-based anti-CD19 CAR T cell therapy to the clinic with a future partner.”

This accomplishment builds upon another first instance of engineering human T cells via a linear DNA amplicon produced, designed and manufactured via LineaRx’s PCR technology in late 2018.  The first instance demonstrated a linear DNA amplicon that contained the complete gene that encoded production of Green Fluorescent Protein (GFP). As seen in the microscope image below, the uptake and subsequent expression of the PCR-generated GFP gene fragment in hundreds of human T cells, facilitated by high-throughput electroporation, created a “constellation” of green fluorescent cells.

In October 2018, LineaRx announced the signing of an exclusive North American licensing and research services agreement with iCell Gene Therapeutics for an anti-CD19 CAR T therapy. Leveraging Applied DNA’s expertise in large-scale PCR-based production and chemical modification of DNA, LineaRx will utilize its NVPF platform to develop and produce expression vectors for CAR T therapies, including for LinCART19™, its non-viral, plasmid-free anti-CD19 CAR T drug candidate.

As discussed at the LinearRx Analyst Day in December 2018, the CAR-T gene construct upon which LinCART19 is based, led to 3 of 3 complete remissions in patients with acute lymphocytic leukemia (ALL) at 6 months after a single low-dose treatment in a clinical trial conducted in China under local regulations.  While these promising clinical results provide evidence in the value of the genetic code utilized, the CAR T cells were transfected via viral vector. LinCART19 will utilize linear DNA transfected by either electroporation, soluporation, or other mode of delivery into T Cells.

Without the use of viral vectors or plasmids, LineaRx’s NVPF manufacturing platform holds numerous potential advantages over existing viral/plasmid-based CAR T approaches offering the possibility of more efficient, affordable and safer gene therapies for patients.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.  Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

program contact:  Brian Viscount, 631-240-8877, brian.viscount@adnas.com
investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
web: www.adnas.com, www.linearxdna.com
twitter: @APDN, @LineaRxDNA

CertainT blended towels will arrive at stores this month

New York – Loftex has announced the first retail introduction of its bath towels including recycled PET (rPET) source-verified by the CertainT platform.

Arriving at retail this month, the towels were originally introduced to consumers via e-commerce. The CertainT tagging and tracing platform is provided by Applied DNA Sciences, which specializes in PCR-based DNA manufacturing for product authenticity and traceability.

Loftex created the eco-friendly towel, which is partially comprised of rPET materials, as part of its commitment to sustainability both in manufacturing and finished products.

Premium, Certified, Verified Recycled Polyester Towels Available at Retail This Month

New York, NY, April 2, 2019. Loftex, a leading manufacturer of high-quality towels, today announced that the first retail introduction of their bath towels including recycled PET (rPET) source-verified by the CertainT^® platform are now available at US retail this month. The CertainT tagging and tracing platform is provided by Applied DNA Sciences, Inc. (Nasdaq: APDN) (“Applied DNA”), a leader in PCR-based DNA manufacturing for product authenticity and traceability. Loftex introduced the eco-friendly towel, partially comprised of rPET materials as part of their commitment to sustainability both in their factory and their product.

What started with e-commerce venues, now will hit retail floors across the country in the second calendar quarter of 2019. Loftex markets and sells bath and beach towels with CertainT source verification for rPET through an exclusive licensing agreement with Applied DNA. Additional products utilizing CertainT source-verification for rPET will continue to be introduced in towels and other home products this year.

The Loftex cotton-polyester blend terry towels feature polyester derived from 100 percent post-consumer recycled polyester. The recycled polyester is known as rPET (polyethylene terephthalate). The recycled polyester fibers are blended with cotton so the towel has the best of both fibers. The blend provides superior absorbency, dries quickly in the dryer and on the towel rod, is resistant to odor and mildew, and stays soft wash after wash. By using Applied DNA’s CertainT platform, the recycled nature of the rPET component of the towel can be verified by detecting an indelible molecular tag, thus ensuring rPET authenticity and origin in the finished product.

Charles Gaenslen, CEO of Loftex Home, said “Loftex consistently strives to find better, more efficient and more intelligent ways to do things. Our new towels embody this mission, and the use of Applied DNA’s CertainT platform reinforces our commitment to use the most technologically advanced methods to ensure our products are true to their sustainable claims.”

Dr. James A. Hayward, CEO of Applied DNA, said “We are committed to differentiating leading companies, like Loftex, by giving their customers a premier authentication system reinforced by CertainT.”

About Loftex
Loftex has established a global reputation for leadership in innovation, fashion, quality, sustainability and value throughout the world. Product innovation in sustainability and commitment to the environment go deep into the heart of what makes Loftex tick. Loftex is committed to make the best product for their consumer while never taking their eyes off of how to make that product with the least possible impact on the environment.

Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, 212-838-3777, shurry@lhai.com
media contact: Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com
program contact: MeiLin Wan, 631-240-8849, meilin.wan@adnas.com
web: www.adnas.com
Twitter: @apdn

DNA tags identifying cotton throughout its journey to consumers.

What are the factors that drive a consumer’s decision to purchase a cotton apparel item? Is it important for them to be able to know from which U.S. cotton production operation the fiber in that apparel item was grown and harvested?

According to Cotton Incorporated’s Lifestyle Monitor Survey, more than 52 percent of U.S. consumers say they are interested in knowing where the cotton in a clothing item comes from before purchasing it. Nearly a third of consumers (32 percent) say knowing information on a product’s environmental footprint would influence their decision to purchase a clothing item.

Applied DNA to Receive Staged Payments Totaling $5M Over the Next Four-Months
Agreement Calls for Annual Payment Minima that Scale from $7 Million in Year 3 to $20 Million in Year 15
Applied DNA Technology to Power ETCH BioTrace System to Verify Legal Cannabis and Hemp Markets Globally

STONY BROOK, N.Y., and PANAMA CITY, PANAMA, March 29, 2019. – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, and TheraCann International Benchmark Corporation (“TheraCann”), a leading global full service legal cannabis and hemp consultancy, announced that they have entered into an exclusive licensing and cooperation agreement (the “Agreement”) that grants TheraCann’s wholly-owned subsidiary, ETCH BioTrace, S.A., the use of Applied DNA’s CertainT^® supply chain integrity platform technology within the global legal cannabis and hemp markets. Under the terms of the Agreement, a $5 million up-front licensing fee is payable to Applied DNA over a four-month period beginning on or before April 15, 2019, and completed by August 15, 2019.

Pursuant to the Agreement, Applied DNA will be the exclusive supplier of molecular tags (provided as SigNature^®), molecular tag application systems and molecular tag authentication systems for TheraCann’s ETCH biotrace seed-to-sale-tracking system. The Parties will jointly market and sell the system, with a profit share after the recoupment of initial investments. The Agreement also calls for specific annual minimum payment milestones to Applied DNA, starting in year two, and scaling from $7M in year three to $20M in year fifteen.“

This Agreement – containing the largest payment transaction in our company history – demonstrates further validation of our DNA technology platform and its commercialization across industries where compliance, control and tracking are essential to marketplace safety and security,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “The impact on our balance sheet is beneficial and will allow us to respond to the requests for pre-commercial pilots we have already received. We believe the growing demand for legalized cannabis is driving the creation of the industry’s global supply chains and is accelerating the need for solutions to secure and validate them from inception through consumption, destruction and/or recall. Powered by our CertainT platform, TheraCann’s ETCH biotrace system can offer the global legal cannabis and hemp industry the unparalleled ability to ensure true authentication and provenance verification. Given TheraCann’s growing standing in the industry, and in conjunction with TheraCann’s Benchmark SOLUTION™, full turn-key cannabis project offering, we believe that this Agreement effectively places Applied DNA at the heart of a fast-growing industry.”

Jason Warnock, CEO of TheraCann International stated, “The marketplace has responded with gusto to our shared ETCH biotrace platform. Multiple letters of intent from numerous countries that wish to protect their licensed cannabis supply chain to maximize international export opportunities already anticipate commercial trials, and quotations are with customers for large scale supply.”

About TheraCann International Corporation
Founded in 2016, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients plan, design, implement and manage their cannabis businesses. Integrating nearly 3.5 million square feet of cannabis operations and the successful launch of groundbreaking Enterprise Resource Planning and Compliance (ERP+C) software, vertical computer automatex cannabis aeroponic cultivation systems (Sprout AI) and patented genetic tracking and diversion prevention systems (ETCH BioTrace), TheraCann provides cannabis-related businesses with solutions to fit their international banking and cannabis license regulatory requirements.

More information about TheraCann is available at www.theracann.solutions, www.etchbio.solutions, www.sproutai.solutions, and www.OS2.solutions. Follow us on Twitter or LinkedIn.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

For Applied DNA:
investor contact: Sanjay M. Hurry, 212-838-3777, shurry@lhai.com
program/media contact: John Shearman, 631-240-8838, john.shearman@adnas.com
web: www.adnas.com
twitter: @APDN

For TheraCann Benchmark International:
investor contact: Jason Warnock, CEO, +1 (844) 877-2649 ext.3002, jwarnock@theracanncorp.com
program contact: Chris Bolton, COO, +1 (844) 877-2649 ext. 3004, cbolton@theracanncorp.com
media contact: Celia Villarreal Osorio, Director Marketing, +1 (844) 877-2649 ext. 3044, cvillarreal@theracanncorp.com
web: www.theracann.solutions
twitter: @theracanncorp
LinkedIn: theracann-corp

Collaboration to study antigen-specific immune responses aimed at achieving therapeutic effects

STONY BROOK, N.Y., March 1, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement (“JDA”) entered into in September 2018.Per the JDA, LineaRx and Takis/Evvivax will jointly develop linear DNA expression amplicons for TK7 and ConTRT, two of Takis/Evvivax’s anti-cancer vaccine candidates, utilizing LineaRx’s validated linear DNA technology. Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax vaccine candidates will be delivered to pre-clinical animal models via Takis/Evvivax’s proprietary electroporation technology.

In 2018, LinearRx and Takis/Evvivax’s collaboration showed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase that is over-expressed in more than 85% of all cancers. “This year we are using ConTRT, an improved version of our telomerase vaccine and a unique personalized approach which includes an epitope-prediction pipeline and a delivery strategy to achieve an extremely effective cancer vaccine over what has been done previously,” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Each expression amplicon will undergo rigorous quality subject matter testing, immunogenicity testing, followed by a tumor challenge, with results planned for publication later this year.”

“Our collaborations with Takis/Evvivax and other therapy developers are helping to validate LineaRx’s novel technology as a viable alternative to bacterially-produced plasmids, with the potential for increased patient safety and reduced costs, using new quality control protocols for large-scale PCR production at LineaRx. We believe that linear DNA and the establishment of new quality attributes for this new therapeutic field will change the way gene and immune therapies will be performed,” stated Dr. James Hayward, president and CEO of Applied DNA. “Our implementation of testing for new quality attributes will support our preparation to approach FDA to seek approval for clinical study. Our know-how in the fields of therapeutic linear DNA production and the standardized PCR platforms in use at LineaRx enable us to create novel expression amplicons. We are extremely pleased with the progress we are making with Takis/Evvivax under our JDA.”

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.  Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

In all forms of gene therapy, DNA exerts its influence from within the nucleus. Recombinant events for circular DNA are permanent and alter the genomes of the affected cells and their progeny. The fundamental challenge of all gene and cellular therapies is safety. Recent studies have elaborated “unintended consequences” when plasmid and viral vectors are combined that may pose future risks for treated patients.

When linear DNA enters the nucleus, it does not need to be incorporated into the genome in to be temporarily expressed as the intended proteins product. LineaRx posits that for the effectiveness of genetic vaccines or genetic immune therapies, transient expression may be sufficient.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019 that is available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.EVVIVAX, whose name is derived from Engineered Veterinary Vectored Immunotherapy and Vaccines, is a spin-off of Takis Biotech. EVVIVAX pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on viral vectors and DNA platform technologies. EVVIVAX frontline candidates are two therapeutic cancer vaccines for canine tumors: Tel-eVax and Erb-eVax. EVVIVAX aims at translating scientific breakthrough achievements in Cancer Immunotherapy into marketed innovative products in Veterinary and subsequently in Human Oncology.Visit www.evvivax.com for more information.Takis is a Biotech Company created in November 2009 by a group of scientists from IRBM, a Research Center in near Rome, formerly part of the global network of Merck Research Laboratories (MRL). The group has more than 15 years of experience and an established track record in drug discovery in Oncology and is recognized for the conception and implementation of a number of innovative technologies. One of the main assets of Takis is the expertise in in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis pipeline include four Cancer Vaccine candidates based on this technology. Takis is also actively involved in the generation of humanized monoclonal antibodies for use in Oncology and Infectious Diseases.Visit www.takisbiotech.it for more information.

program contact:  Brian Viscount, 631-240-8877, brian.viscount@adnas.com
investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
web: www.adnas.com, www.linearxdna.com
twitter: @APDN, @LineaRxDNA

The industry has finally realized the extent of the impact fraudulent goods have on brand integrity—and bottom lines.

Though many in sourcing and operations may have long gotten the sense that knock-offs of their products were being produced, many thought little of it provided it didn’t impact their ability to meet delivery, margins and quality. Until now, that is.